North America

Halo Neuroscience procures $1 mln from FPC

Future Planet Capital has acquired a stake in Halo Neuroscience for $1 million. Based in San Francisco, Halo Neuroscience is a creator of Halo Sport, a neurostimulation headset.

Microsoft Ventures rebrands as M12

According to a blog post on its site, Microsoft Ventures has rebranded as M12. The reasons given for the name change are to avoid confusion with Microsoft Scaleup and clarify how M12 works with startups.

Sky9 Capital raises $200 mln for third fund

Sky9 Capital, a China-focused venture firm, has closed its third fund at a hard cap of $200 million. The fund's limited partners include institutional investors, family foundations and entrepreneurs.

Datavant inks $40.5 mln, also acquires Universal Patient Key

San Francisco-based Datavant, which helps healthcare organizations safely link their data to improve medical research and patient care, has raised $40.5 million in financing. The lead investors were Roivant Sciences and Travis May. Also, Datavant has acquired Universal Patient Key, a provider of HIPAA-compliant de-identification services for healthcare data. No financial terms were disclosed.

Attenua Inc nabs $35 mln Series A

Attenua Inc, a developer of new chronic cough treatments, has closed $35 million in Series A financing. Omega Funds led the round with participation from investors that included Abingworth, OrbiMed and Redmile Group LLC.

Andra Capital collects over $500 mln for fund

San Francisco-based Andra Capital has raised more than $500 million for its blockchain-focused late-stage technology growth fund. According to the company, it expects to raise $1 billion for the pool.

Minim pulls in $2.5 mln seed

Manchester, New Hampshire-based Minim, an internet of things platform whose technology protects connected devices and assures fast WiFi in homes, has secured $2.5 million in seed funding. Flybridge Capital Partners and Founder Collective led the round.

OrbiMed leads Series C round for Synthorx

La Jolla, California-based Synthorx Inc, a developer of novel protein therapeutics, has raised $63 million in Series C financing. OrbiMed led the round with participation from Medicxi, Osage University Partners, Avalon Ventures, RA Capital Management and Correlation Ventures. In addition to the funding, Dr. Peter Thompson and Vickie Capps will join the Synthorx board of directors.

NovellusDx snags $6 mln

Jerusalem-based NovellusDx, a provider of functional genomics, has raised $6 million in funding. The investors were Helsinn Group, Bio Capital Impact Fund and Windham Venture Partners.

Crescendo Biologics rakes in $70 mln Series B

UK-based Crescendo Biologics Ltd, a biopharmaceutical company, has closed $70 million in Series B financing. Andera Partners led the round with participation from other investors that included Quan Capital.